Nanomedicine company Nanobiotix elects former Aventis vice chairman
and CFO Patrick Langlois as its chairman
Podcast available at www.medtechmatters.com
PARIS (Business Wire EON/PRWEB ) May 12, 2008 --
Nanobiotix,
an emerging nanomedicine company focused on cancer therapy, announced
today that it has elected Patrick Langlois as chairman of its
non-executive board, effective immediately.
Since March 1, 2005, Mr. Langlois has served as a General Partner with PJL
CONSEILS, a consulting firm specializing in strategy, corporate
development, and M&A activities for healthcare companies. Prior to PJL,
he was vice chairman of the management board and chief financial officer
at Aventis (created by the merger of Rhône-Poulenc
and Hoechst) from May 2002 to September 2004, and executive vice
president and chief financial officer of Aventis from December 1999 to
May 2002.
At Aventis, Mr. Langlois was responsible for finance, corporate
development, and supervision of the company’s
dermatology, protein therapeutics, and animal health businesses. Earlier
in his career, he was employed by Rhône-Poulenc
Group from 1975 to 1999, most recently as chief financial officer
and member of the executive committee. In addition to Nanobiotix, Mr.
Langlois also is a board member of Shire Pharmaceuticals (UK), Scynexis
(USA), and Exonhit Therapeutics (France). In addition, Mr.
Langlois has served as a senior advisor to JP Morgan Healthcare
since December 2006.
“The addition of such an accomplished industry
veteran as Patrick Langlois bears strong testimony to the significant
opportunity ahead of Nanobiotix,” said Laurent
Levy, Ph.D.,
chief executive officer of Nanobiotix. “We
look forward to reaping the benefits of Patrick’s
considerable talent and abundant experience related to accessing the
capital markets and building strong strategic partnerships.”
“The Company’s NanoXray
platform has the potential to be a dramatic innovation in cancer
therapy, based on a technology that is designed to allow destruction
of cancer cells only,” added Patrick
Langlois. “I am very proud to be part of this
important mission.”
ABOUT NANOBIOTIX
Nanobiotix is an emerging nanomedicine company combining dramatic
advances in nanotechnology and molecular biology to develop nanoXray™—
a technology platform
that is expected to be turned ‘on’
and ‘off’
outside the body to selectively treat a variety of cancers safely
and noninvasively. Use of NanoXray is intended to resolve
radiation therapy’s biggest drawback:
destruction of healthy tissue and its subsequent deleterious side
effects when a high dose of x-ray is necessary. The core of a nanoXray
nanoparticle is an inactive and inert substance—not
a drug—that can subsequently be activated in
order to locally (intratumor) increase the dose of x-ray, which is then
expected to lead to higher efficiency. After nanoXray nanoparticles
accumulate in the target tissues, a standard x-ray is applied that is
intended to generate a local therapeutic effect, designed to destroy
only the targeted tumor cells. This mechanism suggests total
control of the intended therapeutic effect.
See the original story at: http://eon.businesswire.com/releases/langlois/nanobiotix/prweb935664.htm
Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/RW1wdC1Qcm9mLUluc2UtU3F1YS1DcmFzLVplcm8=
Bookmark -
Del.icio.us |
Furl It |
Technorati |
Ask |
MyWeb |
Propeller |
Live Bookmarks |
Newsvine |
TailRank |
Reddit |
Slashdot |
Digg |
Stumbleupon |
Google Bookmarks |
Sphere |
Blink It |
Spurl
|
